Serum Vascular Endothelial Growth Factor (VEGF) and Interleukin-8 (IL-8) Levels in Small Cell Lung Cancer

Taş, Faruk; Duranyıldız, Derya; Oğuz, Hilal; Çamlıca, Hakan; Yasasever, Vildan; Topuz, Erkan

doi:10.1080/07357900600814771

Cited by 51 publications

(37 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Guida and colleagues (46) have reported that IL8 was unrelated with prognoses in patients with metastatic melanoma, even though the group with the highest levels of IL8 presented the lowest median OS. Other groups have reported lack of association of IL8 and prognosis (34,(47)(48)(49). Complexity of IL8 functions, technical issues, and/or characteristics of the selected patient populations may explain such discrepancies.…”

Section: Discussionmentioning

confidence: 86%

Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins

Sanmamed

Carranza-Rua

Alfaro

et al. 2014

Clinical Cancer Research

217

158

View full text Add to dashboard Cite

Purpose: Interleukin-8 (IL8) is a chemokine produced by malignant cells of multiple cancer types. It exerts various functions in shaping protumoral vascularization and inflammation/immunity. We evaluated sequential levels of serum IL8 in preclinical tumor models and in patients to assess its ability to estimate tumor burden.Experimental Design: IL8 levels were monitored by sandwich ELISAs in cultured tumor cells supernatants, tumor-xenografted mice serum, and in samples from 126 patients with cancer. We correlated IL8 serum levels with baseline tumor burden and with treatment-induced changes in tumor burden, as well as with prognosis.Results: IL8 concentrations correlated with the number of IL8-producing tumor cells in culture. In xenografted neoplasms, IL8 serum levels rapidly dropped after surgical excision, indicating an accurate correlation with tumor burden. In patients with melanoma (n ¼ 16), renal cell carcinoma (RCC; n ¼ 23), non-small cell lung cancer (NSCLC; n ¼ 21), or hepatocellular carcinoma (HCC; n ¼ 30), serum IL8 concentrations correlated with tumor burden and stage, survival (melanoma, n ¼ 16; RCC, n ¼ 23; HCC, n ¼ 33), and objective responses to therapy, including those to BRAF inhibitors (melanoma, n ¼ 16) and immunomodulatory monoclonal antibodies (melanoma, n ¼ 8). IL8 concentrations in urine (n ¼ 18) were mainly elevated in tumors with direct contact with the urinary tract.Conclusions: IL8 levels correlate with tumor burden in preclinical models and in patients with cancer.

show abstract

Section: Discussionmentioning

confidence: 86%

Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins

Sanmamed

Carranza-Rua

Alfaro

et al. 2014

Clinical Cancer Research

217

158

View full text Add to dashboard Cite

show abstract

“…Human SCLC cells express functional VEGF receptor (VEGFR)-2, VEGFR-3 and platelet-derived growth factor receptor (PDGFR)-β [Tanno et al 2004;Ioannou et al 2009]. Patients with SCLC express increased levels of serum VEGF and high pretreatment levels of VEGF are associated with poor response to chemotherapy and reduced survival [Ustuner et al 2008;Tas et al 2006;Salven et al 1998;Zhan et al 2009]. In addition, stem cell factor and its receptor, KIT, are coexpressed in up to 70% of SCLC cell lines and clinical SCLC samples.…”

Section: Molecular Targeting Agentsmentioning

confidence: 99%

Relapsed small cell lung cancer: treatment options and latest developments

et al. 2014

View full text Add to dashboard Cite

According to recent analyses, there was a modest yet significant improvement in median survival time and 5-year survival rate of limited stage small cell lung cancer (SCLC) in North America, Europe, Japan and other countries over the last 30 years. The median survival time of limited stage SCLC is 15-20 months and 5-year survival rate is 15% or less. In terms of extensive stage SCLC, a median survival time of 9.4-12.8 months and 2-year survival of 5.2-19.5% are still disappointing. Despite being highly sensitive to first-line chemotherapy and radiotherapy treatments, most patients with SCLC experience relapse within 2 years and die from systemic metastasis. While several clinical trials of cytotoxic chemotherapies and molecular targeting agents have been investigated in the treatment of relapsed SCLC, none showed a significant clinical activity to be able to exceed topotecan as second-line chemotherapy. There are problematic issues to address for relapsed SCLC, such as standardizing the treatment for third-line chemotherapy. Topotecan alone was the first approved therapy for second-line treatment for relapsed SCLC. Amrubicin is a promising drug and a variety of trials evaluating its efficacy have been carried out. Amrubicin has shown superiority to topotecan in a Japanese population, but was not superior in a study of western patients. There are some controversial issues for relapsed SCLC, such as treatment for older patients, third-line chemotherapy and efficacy of molecular targeting therapy. This article reviews current standard treatment, recent clinical trials and other topics on relapsed SCLC.

show abstract

“…This clinical correlation has not been definitively studied in SCLC, due in part to difficulty in obtaining SCLC biopsy samples (reviewed in [37]). Although the prognostic value of serum VEGF levels in SCLC patients in unclear [38,39], the role of angiogenesis in tumor progression and the success of anti-angiogenic agents across various tumor types has prompted investigation of angiogenic targeting in SCLC.…”

Section: Angiogenesis: Targeting Tumor-associated Vascular Growthmentioning

confidence: 99%

Fast, hungry and unstable: finding the Achilles’ heel of small-cell lung cancer

Hann

Rudin

2007

Trends in Molecular Medicine

View full text Add to dashboard Cite

Over 95% of patients with small-cell lung cancer (SCLC) die within five years of diagnosis. The standard of care and the dismal prognosis for this disease have not changed significantly over the past 25 years. Some of the characteristics of SCLC that have defined it as a particularly virulent form of cancer -rapid proliferation, excessive metabolic and angiogenic dependence, apoptotic imbalance and genetic instability -are now being pursued as tumor-specific targets for intervention both in preclinical and early phase clinical studies. Here, we summarize areas of ongoing anti-cancer drug development, including classes of agents that target essential pathways regulating proliferation, angiogenesis, apoptotic resistance, chromosomal and protein stability, and cell-cell and cell-matrix interaction.

show abstract

Serum Vascular Endothelial Growth Factor (VEGF) and Interleukin-8 (IL-8) Levels in Small Cell Lung Cancer

Cited by 51 publications

References 17 publications

Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins

Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins

Relapsed small cell lung cancer: treatment options and latest developments

Fast, hungry and unstable: finding the Achilles’ heel of small-cell lung cancer

Contact Info

Product

Resources

About